GLP-1 Receptor Stabilizers for Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods face challenges in maintaining the monodispersity and stability of the glucagon-like peptide 1 (GLP-1) receptor during purification and crystallization processes, which are crucial for structural determination and drug development.
Innovation Solution
Development of specific compounds that act as stabilizers, potentiators, or modulators of the GLP-1 receptor, enabling its stabilization and facilitating structural analysis by maintaining a functional, monodisperse state throughout purification and crystallization trials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional purification and crystallization methods are used for GLP-1 receptor, then the structural determination process can proceed, but the receptor loses monodispersity and stability during the process
Solution Approach 1:
The patent introduces small molecule compounds as intermediary stabilizers that bind to the GLP-1 receptor and maintain its functional conformation. These compounds act as mediators between the receptor and the purification/crystallization process, preventing aggregation and degradation while allowing the receptor to remain monodisperse and stable throughout the structural determination workflow.
Solution Approach 2:
The patent employs compounds that induce parameter changes in the receptor's conformational state, stabilizing it in a specific functional form. By changing the molecular parameters (binding affinity, conformational rigidity, solubility characteristics) through small molecule interaction, the receptor maintains its stability and monodispersity under varying purification and crystallization conditions.
2Measurement precision
If high-resolution structural determination is achieved, then drug development can be enhanced, but extensive purification and crystallization trials are required
Solution Approach 1:
The patent applies stabilizing compounds to the GLP-1 receptor before initiating purification and crystallization trials. This preliminary stabilization action ensures the receptor remains in a crystallization-competent state throughout the process, significantly reducing the number of trials needed and accelerating the path to high-resolution structure determination.
Solution Approach 2:
The stabilizing compounds maintain the receptor in a continuous functional state throughout the entire purification and crystallization workflow. This continuity prevents degradation and aggregation events that would otherwise require restarting trials, thereby reducing time loss and enabling uninterrupted progression toward high-resolution structural determination.
3Ease of manufacture
If the GLP-1 receptor is stabilized for crystallization, then structural coordinates can be obtained for drug development, but specific stabilizing compounds are required
Solution Approach 1:
The patent identifies stabilizing compounds with multi-functional properties that simultaneously achieve receptor stabilization, maintain monodispersity, and facilitate crystallization. These universal compounds simplify the overall process by combining multiple functions in a single agent, reducing protocol complexity while enabling structural determination and subsequent drug development applications.
Data Source
AI summary
Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP(1-42), PTH(1-34), Glucagon(1-29), GLP-2(1-33), GLP-1(7-36), GLP-1(9-36), oxyntomodulin and exendin variants.